Back to search

Article

The Impact of PIK3CA Mutations and Inflammation–Nutritional Biomarkers on Pathological Complete Response in HER2-Positive Early Breast Cancer: A Real-World Cohort Study

2026-07-21

Abstract excerpt

<h4>Background: </h4> /Objectives: Although dual HER2-targeted neoadjuvant therapy improves pathological complete response (pCR) rates in HER2-positive early breast cancer (EBC), a substantial proportion of patients have residual disease. We evaluated the association between PIK3CA mutations, inflammation–nutritional biomarkers, and pCR. <h4>Methods:</h4> This retrospective, single-center cohort study included 50...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3434e340-f7db-5ee7-b726-31151e6b4a40
DOI
10.20944/preprints202607.1522.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Impact of PIK3CA Mutations and Inflammation–Nutritional Biomarkers on Pathological Complete Response in HER2-Positive Early Breast Cancer: A Real-World Cohort StudyDOI 10.20944/preprints202607.1522.v1
Immune Effective Score As A Predictor Of Response To Neoadjuvant Trastuzumab Therapy And A Prognostic Indicator For HER2-positive Breast CancerSemantic proximity
Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.Semantic proximity
HER3 Expression and PIK3CA Mutational Status Predict Pathological Response of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients.Semantic proximity
Predictive factors for response to neoadjuvant therapy in breast cancer.Semantic proximity
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)Semantic proximity
Hematologic Biomarkers and AI in Breast Cancer: A New Frontier for Risk Stratification and Treatment Response PredictionSemantic proximity
Hematologic Biomarkers and AI in Breast Cancer: A New Frontier for Risk Stratification and Treatment Response PredictionSemantic proximity
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.Semantic proximity
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.Semantic proximity
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Semantic proximity
Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city populationSemantic proximity
Select a neighboring publication to make it the new centre.